^
    Back
    Association details:
    Biomarker:MLL rearrangement
    Cancer:Acute Myelogenous Leukemia
    Drug:Xpovio (selinexor) (XPO1 inhibitor) +
    ziftomenib (KO-539) (Menin-MLL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2023
    Title:

    4168 The Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit the Growth of MLL-r AML

    Published date:
    11/02/2023
    Excerpt:
    The clinical candidate drug ziftomenib, in combination with selinexor, synergistically inhibited the growth of MLL-r AML cell lines (MV4;11 and MOLM13) (CI<1) [Fig.1A].